

JPW

**TRANSMITTAL  
FORM**

(to be used for all correspondence after initial filing)

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	10/776,470; Confirmation 3576	
	Filing Date	2/11/2004	
	First Named Inventor	McBride	
	Art Unit	1616	
	Examiner Name		
Total Number of Pages in This Submission	10	Attorney Docket Number	329532

**ENCLOSURES (check all that apply)**

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Information Disclosure Statement (2 pages) 10 Foreign patent references; 50 non-patent literature documents
<b>Remarks</b> The Director is hereby authorized to charge any additional fee(s) or any underpayment of fee(s) under 37 CFR 1.16 and 1.17; credit any overpayments to the Deposit Account No. 06-0029.		

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm	FAEGRE & BENSON LLP		
Signature			
Printed Name	Richard A. Nakashima		
Date	10/2/06	Reg. No.	42,023

**CERTIFICATE OF TRANSMISSION/MAILING**

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Signature			
Typed or printed name	Laura S. Mellblom	Date	10-2-06

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


In re the Application of:

MCBRIDE

Application No.: 10/776,470

Filed: 2/11/2004

For: THERAPEUTIC AND DIAGNOSTIC  
CONJUGATES FOR USE WITH  
MULTISPECIFIC ANTIBODIES



Examiner:

Art Unit: 1616

INFORMATION DISCLOSURE STATEMENT  
(37 C.F.R. §§ 1.97(b)(3) and 1.98)

MAILSTOP: AMENDMENT  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:


The Examiner is requested to consider the references noted on the enclosed Form PTO/SB/08A (Substitute for form 1449A/PTO) during examination of the above-identified application. These references are submitted for the Examiner's consideration and are submitted pursuant to the duty of disclosure under 37 C.F.R. § 1.56. In submitting these references, no representation is made or implied that the references are or are not material to the examination of the application. The Examiner is encouraged to make his or her own determination of materiality.

Should any additional fees and/or any underpayment of fee(s); credit any overpayments be deemed necessary, such fees may be charged to Deposit Account No. 06-0029.


Should the examiner have any questions concerning the relevance of any reference cited in this disclosure, please contact the undersigned attorney.

Dated: October 2, 2006

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Richard A. Nakashima', written over a horizontal line.

Richard A. Nakashima  
Registration No. 42,023  
Customer No. 35657



Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 8

**Complete if Known**

Application Number	10/776,470; Confirmation 3576
Filing Date	2/11/2004
First Named Inventor	McBride
Art Unit	1616
Examiner Name	
Attorney Docket Number	329532

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
	1	US-5,274,076	12/12/1993	Barbet et al	
	2	US- 6,096,289	8/2000	Goldenberg	
	3	US- 5,683,694	11/4/1997	Bagshawe et al.	
	4	US- 5,693,762	12-02-1997	Queen et al.	
	5	US- 5,837,242	11-17-1998	Holliger et al.	
	6	US- 6,121,424	9-19-2000	Whitlow et al.	
	7	US- 2002/0006379	1-17-2002	Hansen et al.	
	8	US- 6,126,916	10/3/2000	McBride	
	9	US- 6,077,499	6/20/2000	Griffiths	
	10	US- 6,010,680	1/4/2000	Govindan et al.	
	11	US- 5,959,083	9/28/1999	Bosslet et al.	
	12	US- 5,776,095	7/7/1998	Goldenberg	
	13	US- 5,776,094	7/7/1998	Goldenberg	
	14	US- 5,776,093	7/7/1998	Goldenberg	
	15	US- 5,772,981	6/30/1998	Govindan et al.	
	16	US- 5,753,206	5/19/1998	McBride et al.	
	17	US- 5,746,996	5/5/1998	Govindan et al.	
	18	US- 5,697,902	12/16/1997	Goldenberg	
	19	US- 5,591,828	7/1/1997	Bosslet et al.	
	20	US- 5,328,679	7/12/1994	Hansen et al.	


**FOREIGN PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	21	WO 99/66951 A2	12/29/1999	Hansen		
	22	WO 00/34317	6/15/2000	Carr		
	23	WO 9808875	3/5/1998	Bohlen		
	24	WO 9604313	2/15/1996	Goldenberg		
	25	EP 0623675	9/11/1994	Ahrweiler		
	26	IE 921782	12/16/1992	Bosslet		
	27	EP 0511011A	10/28/1992	Randle		
	28	EP 0419387	11/20/1996	Barbet		
	29	EP 0517024 A2	12/9/1992	Bosslet		

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08B(07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 8

**Complete if Known**

Application Number	10/776,470; Confirmation 3576
Filing Date	2/11/2004
First Named Inventor	McBride
Art Unit	1616
Examiner Name	
Attorney Docket Number	329532

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	30	BOISFERON, Hillairet de et al., "Enhanced Targeting Specificity to Tumor Cells by Simultaneous Recognition of Two Antigens" Bioconjugate Chem. 2000 11, 252-460	
	31	PLUCKTHUN et al., "New protein engineering approaches to Multivalent and bispecific antibody fragments," Immunotechnology 3 (1997) 83-105	
	32	PACK et al., "Tetavalent Miniantibodies with High Avidity Assembling in Escherichia Coli," J. Mol. Biol. (1995) 246, 28-34	
	33	SHARKEY et al., "A Universal Pretargeting System for Cancer Detection and Therapy Using Bispecific Antibody," Cancer Research 63, 354-363 (Jan. 15, 2003)	
	34	KARACAY et al., "Studies on a Humanized anti-CEA x murine anti-(In- DTPA) bispecific antibody construct for radioimmunotherapy of CEA-positive tumors," Proceedings of the American Association for Cancer Research Annual Meeting, Vol. 40, p 644 (March 1999).	
	35	KARACAY et al., "Pretargeting studies with a humanized anti-CEA X Murine anti-(In- DTPA) bispecific antibody construct and Tc-99m/Re-188 labeled peptide," Journal of Nuclear Medicine, Vol. 40, No. 5 Suppl., p. 225 (May 1999).	
	36	GAUTHEROT et al., "Delivery of Therapeutic doses of Radioiodine using Bispecific antibody-targeted bivalent Haptens," Journal of Nuclear Medicine, Vol. 39 (11), pp 1937-43 (Nov. 1998)	
	37	BODERE et al. "Phase I/II trial of two-step radioimmunotherapy in medullary thyroid cancer (MTC) using bispecific anti-CEA/anti-DTPA-in antibody and iodine-131-labeled bivalent hapten," Journal of Nuclear Medicine, Vol. 39, No. 5 Suppl., p 246 (May 1998)	
	38	BARDIES et al. "Bispecific antibody and iodine-131-labeled bivalent hapten dosimetry in patients with medullary thyroid or small-cell lung cancer," Journal of Nuclear Medicine, Vol. 37, pp 1853-1859 (Nov. 1996)	
	39	KRAEBER-BODERE et al., "Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft," Journal of Nuclear Medicine, Vol. 40 (1), pp. 198-24 (Jan. 1999)	
	40	HOSONO et al., "Biodistribution and dosimetric study in medullary thyroid cancer xenograft using bispecific antibody and iodine-125-labeled bivalent hapten," Journal of Nuclear Medicine, Vol. 39 (9), pp 1608-13 (Sept. 1998)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/08A (07-05)



PTO/SB/08B(07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 4 of 8

**Complete if Known**

Application Number	10/776,470; Confirmation 3576
Filing Date	2/11/2004
First Named Inventor	McBride
Art Unit	1616
Examiner Name	
Attorney Docket Number	329532

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	62	KRANENBORG et al., "Development and characterization of anti-renal cell carcinoma x antichelate bispecific monoclonal antibodies for two-phase targeting of renal cell carcinoma," Cancer Research, Vol. 55 (23 Wuppl.), pp 5864S-5867S (Dec. 1, 1995)	
	63	KRANENBORG et al., "Two-Step radio-immunotargeting of renal-cell carcinoma xenografts in nude mice with anti-renal-cell-carcinoma X anti-DTPA bispecific monoclonal antibodies," International Journal of Cancer, Vol. 75 (1), pp 74-80 (Jan. 5, 1998)	
	64	GAUTHEROT et al., "Therapy for colon carcinoma xenografts with bispecific antibody-targeted, iodine-131-labeled bivalent hapten," Cancer, Vol. 80, No. Supp. 12, pp 2618-2623 (Dec. 15, 1997)	
	65	BOSSLET et al., "Generation of bispecific monoclonal antibodies for two phase radioimmunotherapy," British Journal of Cancer, Vol. 63/5, pp 681-686 (1991)	
	66	MANETTI et al., "Intracellular uptake and catabolism of anti-IgM antibodies and bi-specific antibody-targeted hapten by B-lymphoma cells," Int. J. Cancer, Vol. 63(2), pp 250-6 (1995)	
	67	BARBET et al., "Radioimmunotherapy of LS174T colon carcinoma in nude mice using an iodine-131-labeled bivalent hapten combined with an anti-CEAX anti-indium-DTPA bispecific antibody," Tumor Biology, Vol. 18, No. Suppl. 2, p 31 (Sept. 1997)	
	68	MCGUINNESS et al., "Phage diabody repertoires for selection of large number of bispecific antibody fragments," Nature Biotechnology, 14:1149-1154 (1996)	
	69	ALT, et al., "Novel tetravalent and bispecific IgG-like antibody molecules combining single chain diabodies with the immunoglobulin gamma-1 or CH3 region," FEBS LETT, 454: 90-94 (1999).	
	70	OLAFSEN et al., "IgM secretory tailpiece drives multimerisation of bivalent scFv fragments in eukaryotic Cells," Immunotechnology, 4(2):141-153 (1998)	
	71	KIPRIYANOV et al., "Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics," J. Mol. Biol., 293(1):41-56 (1999).	
	72	HAWKINS, et al., "Delivery of Radionuclides to Pretargeted Monoclonal Antibodies Using Dihydrofolate Reductase and Methotrexate in an Affinity System," Cancer Research, Vol. 53, pp 2368-2373, May 1993	

Examiner Signature	Date Considered
-----------------------	--------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Act of 1995, no persons are equal

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(Use as many sheets as necessary)*

Sheet	5	of	8
-------	---	----	---

**Complete if Known**

Application Number	10/776.470: Confirmation 3576
--------------------	-------------------------------

Filing Date	2/11/2004
-------------	-----------

First Named Inventor	McBride
----------------------	---------

Art Unit	1616
----------	------

Examiner Name \_\_\_\_\_

Attorney Docket Number	329532
------------------------	--------


[illegible][illegible]Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*





PTO/SB/08B(07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 6 of 8

**Complete if Known**

Application Number	10/776,470; confirmation 3576
Filing Date	2/11/2004
First Named Inventor	McBride
Art Unit	1616
Examiner Name	
Attorney Docket Number	329532

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	77	GOODWIN, et al., "Pre-Targeted Immunoscintigraphy of Murine Tumors with Indium-111-Labeled Bifunctional Haptens," J. Nucl. Med., Vol. 29, pp 226-234, 1998	
	78	STICKNEY, et al., "Bifunctional Antibody: A binary Radiopharmaceutical Delivery System for Imaging Colorectal Carcinoma," Cancer Research, Vol. 51, pp 6650-6655, December 15, 1991.	
	79	GAUTHEROT, et al., "Therapy for Colon Carcinoma Xenografts with Bispecific Antibody-Targeted, Iodine-131-Labeled Bivalent Hapten," Cancer Supplement, Vol. 80, pp 2618-2623, 1997	
	80	BARBET et al., "Radioimmunodetection of Medullary Thyroid Carcinoma Using Indium-111 Bivalent Hapten and Anti-CEA X Anti-DTPA-Indium," The Journal of Nuclear Medicine, Vol. 39, No. 7, July 1998.	
	81	KRANENBORG, et al. "Development and Characterization of Anti-Renal Cell Carcinoma x Antichelate Bispecific Monoclonal Antibodies for Two-Phase Targeting of Renal Cell Carcinoma," Cancer Research Supplement, Vol. 55, pp 5864s-5867s, December 1, 1995	
	82	CHATZIOANNOU, A., et al., "MICROPET 1: performance Evaluation of a Very High Resolution pet Scanner Proceedings of the 44 <sup>th</sup> Annual Meeting Scientific Papers, Vol. 38, No. 5, May 1997 Supplement	
	83	SCHUHMACHER, et al., "Multistep Tumor Targeting in Nude Mice Using Bispecific Antibodies and a Gallium Chelate Suitable for Immunoscintigraphy with Positron Emission Tomography," Cancer Research, Vol. 55, pp 115-123, January 1, 1995.	
	84	SHARKEY, et al., "Development of a Streptavidin-Anti-Carcinoembryonic Antigen Antibody, Radiolabeled Biotin Pretargeting Method for Radioimmunotherapy of Colorectal Cancer. Studies in A Colon Cancer Xenograft Model," Bioconjugate Chemical, Vol. 8, No. 4, 1997	
	85	ARANO, YASUSHI, et al., "Reassessment of Diethylenetriaminepentaacetic Acid (DTPA) as a Chelating Agent for Indium-111 Labeling of Polypeptides Using a Newly Synthesized Monoreactive DTPA Derivative," J. Med. Chem, Vol 39, pp. 3451-3460, 1996	
	86	BARMAS, A., et al. "Two-Step Strategies for the Diagnosis and Treatment of Cancer with Bioconjugates," Antibody, Immunoconjugates, Radiopharm., Vol. 5, No. 4, pp. 385-395, 1992	
	87	BOS, EBO S., et al. "In Vitro Evaluation of DNA-DNA Hybridization as a Two-Step Approach in Radioimmunotherapy of Cancer," Cancer Research, Vol. 54, pp. 3479-3486, 1994	


Examiner Signature	Date Considered
-----------------------	--------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08B(07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 7 of 8

**Complete if Known**

Application Number	10/776,470; Confirmation 3576
Filing Date	2/11/2004
First Named Inventor	McBride
Art Unit	1616
Examiner Name	
Attorney Docket Number	329532

**NON PATENT LITERATURE DOCUMENTS**


Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	88	GAUTHEROT, et al., "Radioimmunotherapy of LS174T Colon carcinoma in Nude Mice Using an Iodine-131-Labeled Bivalent Hapten Combined with an Anti-CEA X Anti-indium-DTPA Bispecific Antibody," J. Nucl. Med., Vol. 38, p. 7, 1997	
	89	GREENWOOD, F. C., et al., "The Preparation of 131I-Labelled Human Growth Hormone of High Specific Radioactivity," The Biochemical Journal, Vol. 89, pp. 114-123; 1963	
	90	KANEKO, T., "New Hydrazone Derivative of Adriamycin and Their Immunoconjugates--a Correlation between Acid Stability and Cytotoxicity," J. Bioconjugate Chem., Vol. 2, No. 3, pp. 133-141, 1991	
	91	KARACAY, ET AL., "Experimental Pretargeting Studies of Cancer with a Humanized anti-CEA x Murine anti-[In-DTPA] Bispecific Antidoy Construct and a 99mTc-188 Re-Labeled Peptide," Bioconjugate Chem., Vol. 11, pp. 842-854, 2000	
	92	LOSMAN, M. J., et al., "Generation and Monitoring of Cell Lines Producing Humanized Antibodies," Clin. Cancer Research, Vol. 5, (10 Suppl.) pp. 3101s-3105s, 1999	
	93	PENEFSKY, Harvey S., "A Centrifuged-Column Procedure for the Measurement of Ligand Binding by Beef Heart F," Methods in Enzymology, Part G, Vol. 56, pp. 527-530, 1979	
	94	WANG, SHING-MING, et al., "Specific Activation of Glucuronide Prodrugs by Antibody-targeted Enzyme Conjugates for Cancer Therapy," Cancer Res., Vol. 52, pp. 4484-4491, 1992	
	95	DE JONGE, JAN, et al., "Production and Characterization of Bispecific Single-Chain Antibody Fragments," Molecular Immunology, Vol. 32, No. 17/18, pp. 1405-1412, 1995	
	96	BODEN, V., et al., "Preliminary Study of the Metal Binding Site of an Anti-DTPA-Indium Antibody by Equilibrium Binding Immunoassays and Immobilized Metal Ion Affinity Chromatography," Bioconjugate Chem., Vol. 6, pp. 373-379, 1995	
	97	GOLD et al., Cancer Research, 50 6405-6409, 1990	
	98	VAN SPRIEL, et al., "Immunotherapeutic Perspective for Bispecific antibodies" Immunology Today, 21, 391-396, 2000	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08B(07-06)

Approved for use through 09/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 8 of 8

**Complete if Known**

Application Number	10/776,470; Confirmation 3576
Filing Date	2/11/2004
First Named Inventor	McBride
Art Unit	1616
Examiner Name	
Attorney Docket Number	329532

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	99	KONTERMANN, Roland E., "Intracellular and Cell Surface Displayed single-chain Diabodies" Journal of Immunological Methods 226 (1999) 179-188	
	100	DUBEL, S., "Reconstitution of human pancreatic RNase from two separate fragments fused to different single chain antibody fragments: on the way to binary immunotoxins" Tumor Targeting (1999) 4, 37-46 XP009010728	
	101	HAYDEN, M. "Single-chain mono- and bispecific antibody derivatives with novel biological properties and antitumour activity from a COS cell transient expression system" Therapeutic Immunology, 1994, 1, 3-15	
	102	YANG "A Genetically Engineered Single-Chain FV/TNF Molecule Possesses the Anti-Tumor Immunoreactivity of FV as well as the Cytotoxic Activity of Tumor Necrosis Factor" Molecular Immunology Vol. 32, No. 12, pp. 873-881, 1995 XP 000653177	
	103	KARACAY, H., et al., "Pretargeting Studies with a Murine Anti-Colon-Specific Antigen-P (CSAp) X Chimeric Anti-[Indium-DTPA] Bispecific Antibody and Technetium-99m-Labeled Peptide" Cancer Biotherapy and Radiopharmaceuticals, Vol. 15, No. 4, 2000, page 412, XP008065412	
	104	KARACAY, H., et al., "Experimental Preatargeting Studies of Cancer with a Humanized anti-CEA Murine anti-[In-DTPA] Bispecific Antibody Construct and a 99mTc-/188Re-Labeled Peptide" Bioconjugate Chem. 2000, 11, 842-854	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.